Since the average age of presentation for CML is 64 years old, 64% of CML patients have a history of hypertension, diabetes, or known atherosclerotic heart disease at the time of initiation of treatment with a second or third generation BCR-ABL TKI [16]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.